{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:58:33Z","timestamp":1782125913334,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81401972"],"award-info":[{"award-number":["81401972"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81401972"],"award-info":[{"award-number":["81401972"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020MH253"],"award-info":[{"award-number":["ZR2020MH253"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020MH253"],"award-info":[{"award-number":["ZR2020MH253"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-78316-3","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:02:30Z","timestamp":1730520150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-\u03baB pathways"],"prefix":"10.1038","volume":"14","author":[{"given":"Qiang-bo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-de","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En-yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"78316_CR1","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099\u20137109. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1443 (2004).","journal-title":"Cancer Res."},{"key":"78316_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1470-2045(08)70317-6","volume":"10","author":"P Johnson","year":"2009","unstructured":"Johnson, P. & Billingham, L. Sorafenib for liver cancer: the horizon broadens. Lancet Oncol. 10, 4\u20135. https:\/\/doi.org\/10.1016\/S1470-2045(08)70317-6 (2009).","journal-title":"Lancet Oncol."},{"key":"78316_CR3","first-page":"2498","volume":"359","author":"HD Palmer","year":"2008","unstructured":"Palmer, H. D. Sorafenib in advanced hepatocellular carcinoma. N Engl. J. Med. 359, 2498 (2008). author reply 2498\u20132499.","journal-title":"N Engl. J. Med."},{"key":"78316_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(08)70285-7 (2009).","journal-title":"Lancet Oncol."},{"key":"78316_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl. J. Med. 359, 378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857 (2008).","journal-title":"N Engl. J. Med."},{"key":"78316_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232\u2013239. https:\/\/doi.org\/10.1016\/j.ccr.2009.01.021 (2009).","journal-title":"Cancer Cell."},{"key":"78316_CR7","doi-asserted-by":"publisher","unstructured":"Zhang, W. et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology 143, 1641\u20131649 e1645, doi: (2012). https:\/\/doi.org\/10.1053\/j.gastro.2012.08.032","DOI":"10.1053\/j.gastro.2012.08.032"},{"key":"78316_CR8","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/leu.2008.58","volume":"22","author":"W Zhao","year":"2008","unstructured":"Zhao, W., Gu, Y. H., Song, R., Qu, B. Q. & Xu, Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia. 22, 1226\u20131233. https:\/\/doi.org\/10.1038\/leu.2008.58 (2008).","journal-title":"Leukemia"},{"key":"78316_CR9","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","volume":"111","author":"MM Hipp","year":"2008","unstructured":"Hipp, M. M. et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 111, 5610\u20135620. https:\/\/doi.org\/10.1182\/blood-2007-02-075945 (2008).","journal-title":"Blood"},{"key":"78316_CR10","doi-asserted-by":"publisher","first-page":"e55945","DOI":"10.1371\/journal.pone.0055945","volume":"8","author":"QB Zhang","year":"2013","unstructured":"Zhang, Q. B. et al. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS One. 8, e55945. https:\/\/doi.org\/10.1371\/journal.pone.0055945 (2013).","journal-title":"PLoS One"},{"key":"78316_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503\u2013510. https:\/\/doi.org\/10.1038\/ni1582 (2008).","journal-title":"Nat. Immunol."},{"key":"78316_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410, 1107\u20131111. https:\/\/doi.org\/10.1038\/35074122 (2001).","journal-title":"Nature"},{"key":"78316_CR13","first-page":"7002","volume":"60","author":"H Nokihara","year":"2000","unstructured":"Nokihara, H. et al. Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res. 60, 7002\u20137007 (2000).","journal-title":"Cancer Res."},{"key":"78316_CR14","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1182\/blood.v97.10.3132","volume":"97","author":"CY Koh","year":"2001","unstructured":"Koh, C. Y. et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood. 97, 3132\u20133137. https:\/\/doi.org\/10.1182\/blood.v97.10.3132 (2001).","journal-title":"Blood"},{"key":"78316_CR15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/sj.leu.2404226","volume":"20","author":"G Jego","year":"2006","unstructured":"Jego, G., Bataille, R., Geffroy-Luseau, A., Descamps, G. & Pellat-Deceunynck, C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through toll-like receptors. Leukemia. 20, 1130\u20131137. https:\/\/doi.org\/10.1038\/sj.leu.2404226 (2006).","journal-title":"Leukemia"},{"key":"78316_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","volume":"19","author":"T Kawai","year":"2007","unstructured":"Kawai, T. & Akira, S. TLR signaling. Semin Immunol. 19, 24\u201332. https:\/\/doi.org\/10.1016\/j.smim.2006.12.004 (2007).","journal-title":"Semin Immunol."},{"key":"78316_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","volume":"60","author":"M Matsumoto","year":"2008","unstructured":"Matsumoto, M. & Seya, T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv Rev. 60, 805\u2013812. https:\/\/doi.org\/10.1016\/j.addr.2007.11.005 (2008).","journal-title":"Adv. Drug Deliv Rev."},{"key":"78316_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1126\/science.1087262","volume":"301","author":"M Yamamoto","year":"2003","unstructured":"Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 301, 640\u2013643. https:\/\/doi.org\/10.1126\/science.1087262 (2003).","journal-title":"Science"},{"key":"78316_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0605978104","volume":"104","author":"T Akazawa","year":"2007","unstructured":"Akazawa, T. et al. Antitumor NK activation induced by the toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. U S A. 104, 252\u2013257. https:\/\/doi.org\/10.1073\/pnas.0605978104 (2007).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"78316_CR20","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.4049\/jimmunol.0901500","volume":"183","author":"T Miyake","year":"2009","unstructured":"Miyake, T. et al. Poly I:C-induced activation of NK cells by CD8 alpha\u2009+\u2009dendritic cells via the IPS-1 and TRIF-dependent pathways. J. Immunol. 183, 2522\u20132528. https:\/\/doi.org\/10.4049\/jimmunol.0901500 (2009).","journal-title":"J. Immunol."},{"key":"78316_CR21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3748\/wjg.v7.i5.630","volume":"7","author":"Y Li","year":"2001","unstructured":"Li, Y. et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J. Gastroenterol. 7, 630\u2013636 (2001).","journal-title":"World J. Gastroenterol."},{"key":"78316_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/MEG.0b013e3283050a67","volume":"20","author":"BW Yang","year":"2008","unstructured":"Yang, B. W. et al. Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice. Eur. J. Gastroenterol. Hepatol. 20, 1077\u20131084. https:\/\/doi.org\/10.1097\/MEG.0b013e3283050a67 (2008).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"78316_CR23","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3892\/ijo_00000454","volume":"35","author":"TL Chiu","year":"2009","unstructured":"Chiu, T. L., Lin, S. Z., Hsieh, W. H. & Peng, C. W. AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells. Int. J. Oncol. 35, 1361\u20131367 (2009).","journal-title":"Int. J. Oncol."},{"key":"78316_CR24","doi-asserted-by":"publisher","first-page":"21216","DOI":"10.18632\/aging.203424","volume":"13","author":"Q Jia","year":"2021","unstructured":"Jia, Q. et al. Dual roles of WISP2 in the progression of hepatocellular carcinoma: implications of the fibroblast infiltration into the tumor microenvironment. Aging (Albany NY). 13, 21216\u201321231. https:\/\/doi.org\/10.18632\/aging.203424 (2021).","journal-title":"Aging (Albany NY)"},{"key":"78316_CR25","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.4049\/jimmunol.0902404","volume":"183","author":"M Krusch","year":"2009","unstructured":"Krusch, M. et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J. Immunol. 183, 8286\u20138294. https:\/\/doi.org\/10.4049\/jimmunol.0902404 (2009).","journal-title":"J. Immunol."},{"key":"78316_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/5584_2019_441","volume":"1237","author":"H Elkhenany","year":"2020","unstructured":"Elkhenany, H., Shekshek, A. & Abdel-Daim, M. El-Badri, N. Stem Cell Therapy for Hepatocellular Carcinoma: future perspectives. Adv. Exp. Med. Biol. 1237, 97\u2013119. https:\/\/doi.org\/10.1007\/5584_2019_441 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"78316_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.gastro.2018.09.051","volume":"156","author":"TF Greten","year":"2019","unstructured":"Greten, T. F., Lai, C. W. & Li, G. Staveley-O\u2019Carroll, K. F. Targeted and Immune-based therapies for Hepatocellular Carcinoma. Gastroenterology. 156, 510\u2013524. https:\/\/doi.org\/10.1053\/j.gastro.2018.09.051 (2019).","journal-title":"Gastroenterology"},{"key":"78316_CR28","first-page":"5737","volume":"35","author":"M Stotz","year":"2015","unstructured":"Stotz, M. et al. Molecular targeted therapies in Hepatocellular Carcinoma: past, Present and Future. Anticancer Res. 35, 5737\u20135744 (2015).","journal-title":"Anticancer Res."},{"key":"78316_CR29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/sj.bjc.6604965","volume":"100","author":"C Alfaro","year":"2009","unstructured":"Alfaro, C. et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer. 100, 1111\u20131119. https:\/\/doi.org\/10.1038\/sj.bjc.6604965 (2009).","journal-title":"Br. J. Cancer"},{"key":"78316_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/1471-2407-13-527","volume":"13","author":"YY Xu","year":"2013","unstructured":"Xu, Y. Y. et al. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo. BMC Cancer. 13, 527. https:\/\/doi.org\/10.1186\/1471-2407-13-527 (2013).","journal-title":"BMC Cancer"},{"key":"78316_CR31","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.7150\/thno.32543","volume":"9","author":"EB Chen","year":"2019","unstructured":"Chen, E. B. et al. The miR-561-5p\/CX(3)CL1 Signaling Axis regulates pulmonary metastasis in Hepatocellular Carcinoma Involving CX(3)CR1(+) natural killer cells infiltration. Theranostics. 9, 4779\u20134794. https:\/\/doi.org\/10.7150\/thno.32543 (2019).","journal-title":"Theranostics"},{"key":"78316_CR32","doi-asserted-by":"publisher","unstructured":"Jung, I. H. et al. In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model. In Vivo 32, 771\u2013781, doi: (2018). https:\/\/doi.org\/10.21873\/invivo.11307","DOI":"10.21873\/invivo.11307"},{"key":"78316_CR33","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","volume":"16","author":"W Zhang","year":"2010","unstructured":"Zhang, W. et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16, 3420\u20133430. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2904 (2010).","journal-title":"Clin. Cancer Res."},{"key":"78316_CR34","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.4049\/jimmunol.179.6.3472","volume":"179","author":"MV Girart","year":"2007","unstructured":"Girart, M. V., Fuertes, M. B., Domaica, C. I., Rossi, L. E. & Zwirner, N. W. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J. Immunol. 179, 3472\u20133479 (2007).","journal-title":"J. Immunol."},{"key":"78316_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jri.2009.03.004","volume":"82","author":"Y Lin","year":"2009","unstructured":"Lin, Y. et al. Effect of TLR3 and TLR7 activation in uterine NK cells from non-obese diabetic (NOD) mice. J. Reprod. Immunol. 82, 12\u201323. https:\/\/doi.org\/10.1016\/j.jri.2009.03.004 (2009).","journal-title":"J. Reprod. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78316-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78316-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78316-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T06:06:46Z","timestamp":1730786806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78316-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78316"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78316-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4124175\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The project design was conducted in line with scientific and ethical principles. The study was performed in accordance with the Declaration of Helsinki. All animal experiments were performed in accordance with relevant guidelines and regulations, and the ethical and animal committee and institutional review board of Qilu Hospital, Shandong University approved this project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u201cNot applicable\u201d in this section.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"26422"}}